Aliskiren as an adjunct therapy for atypical hemolytic uremic syndrome
Authors:
Open Access
- 22 November 2019
- journal article
- editorial
- Published by Oxford University Press (OUP) in Clinical Kidney Journal
- Vol. 13 (1) , 39-41
Abstract
Direct renin inhibitors (DRIs) block the activation of the alternative complement pathway in vitro and could be a treatment option for refractory hypertension in atypical hemolytic uremic syndrome (aHUS). A 20-year-old male presented with primary aHUS complicated by end-stage renal disease and refractory malignant hypertension despite being on five antihypertensive medications at maximum dose. Only a partial response was achieved with aliskiren and eculizumab, but after increasing aliskiren to a supratherapeutic dose, antihypertensive medication was reduced, platelets increased, C3 increased and epoetin alfa requirement decreased. DRI may be an adjunct treatment for malignant hypertension associated with aHUS.Keywords
This publication has 5 references indexed in Scilit:
- Aliskiren inhibits renin-mediated complement activationKidney International, 2018
- Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies ConferenceKidney International, 2017
- Discovery of TAK-272: A Novel, Potent, and Orally Active Renin InhibitorACS Medicinal Chemistry Letters, 2016
- Clinical Pharmacokinetics and Pharmacodynamics of AliskirenClinical Pharmacokinetics, 2008
- Aliskiren, an Oral Renin Inhibitor, Provides Dose-Dependent Efficacy and Sustained 24-Hour Blood Pressure Control in Patients With HypertensionJACC, 2007